In a recent filing, it was disclosed that Peter Altman, serving as the President and CEO of BioCardia, Inc. (NASDAQ:BCDA), has expanded his personal equity position in the firm through a direct purchase of common stock. The transaction took place on April 29, 2026, during which Mr. Altman acquired 5,000 shares at a unit price of $1.11, totaling an investment of $5,550.
This move by the top executive follows a period of significant valuation adjustment for BioCardia. The company's stock has experienced an approximately 8% drop over the last week and has seen a substantial decrease of about 64% over the past year. At the time of these reports, the shares were trading near their 52-week low of $1.00. With this latest transaction accounted for, Mr. Altman now holds 280,766 shares of BioCardia common stock directly.
Clinical and Regulatory Progress
The insider activity coincides with several critical operational milestones for BioCardia. The company recently released its financial results for the fourth quarter of 2025, which indicated a slight rise in expenses alongside a net loss. These financial figures were attributed to the ongoing costs associated with advancing the company's clinical programs.
Central to the company's operations is its CardiAMP therapy. BioCardia has been actively pursuing regulatory pathways for the CardiAMP System, submitting clinical study data from the CardiAMP HF trial to the U.S. Food and Drug Administration (FDA). This submission is part of an effort to secure an accelerated approval pathway, building upon the FDA Breakthrough Designation previously granted for the treatment of ischemic chronic heart failure.
On the international front, BioCardia has made strides in Japan. The Pharmaceutical and Medical Device Agency in Japan provided positive regulatory feedback, stating that the evidence regarding the clinical safety and efficacy of the CardiAMP Cell Therapy is likely sufficient to support market clearance. While the agency accepted the use of foreign clinical data and the proposed approach for introducing the therapy into the Japanese market, it noted that further post-marketing studies will be required. Additionally, the company has secured a Japanese patent for its Heart3D Fusion Imaging software, which serves as a tool for treatment planning and navigation during CardiAMP Cell Therapy procedures.
Market Context and Analysis
The current valuation of BCDA is subject to various analytical perspectives. Some assessments suggest that the stock appears undervalued at its present price levels. As BioCardia continues to navigate the complexities of clinical trials and international regulatory requirements, the company remains focused on expanding its therapeutic reach through its specialized cardiovascular technologies.